$5.73
0.030.53%
Last update: Nov 10, 4:27 PM
Orchestra BioMed Holdings Inc
OBIONASDAQ
Orchestra BioMed rose 39.0% from $4.10 to $5.70, ahead of the S&P 500's +9.8%. Its worst day was May 15 (−9.5%), and its low came Jan 30 at $3.49.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Orchestra BioMed shares rose 10.5%, while the S&P 500 rose 0.9%.
+10.5% · S&P 500 +0.9%
Orchestra BioMed shares rose 11.2%, while the S&P 500 rose 0.7%.
+11.2% · S&P 500 +0.7%
Story events cover the past 12 months · Times ET
Orchestra BioMed closed at its lowest level of the year, 14.9% below where the year started.
−6.4% · S&P 500 −0.3%
EPS of $0.26 beat the $-0.38 estimate on $30.9M revenue (est. $871,174.00).
−4.8% · S&P 500 −1.5%
EPS of $-0.33 beat the $-0.43 estimate on $110,000.00 revenue (est. $512,664.00).
0.0% · S&P 500 +0.6%
Orchestra BioMed shares rose 12.0%, while the S&P 500 rose 1.6%.
+12.0% · S&P 500 +1.6%
EPS of $-0.38 missed the $-0.37 estimate on $88,000.00 revenue (est. $120,536.00).
−1.3% · S&P 500 −0.3%
Orchestra BioMed closed at its highest level of the year, 54.9% above where the year started.
+2.1% · S&P 500 +0.2%
Where it ended: a close of $5.70 on Nov 9, 2026. Up next: Q4 2026 earnings on Mar 11, 2027 (EPS est. $-0.41, revenue est. $109,464.00).
Nothing in the past 12 months.
All OBIO dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for OBIO and SPY from Benzinga historical bars. Not investment advice.
